cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Lansoprazole in Chronic Post Nasal Drip

The purpose of this study is to determine whether aggressive acid suppression with Lansoprazole is effective in the treatment of post nasal drip, and also assess the predictors of response based on clinical and physiologic parameters.

Postnasal drip (PND) is a common complaint that brings patients to the attention of their primary care physicians. It is also one of the most common reasons for patients to seek care from otolaryngologists. Traditionally, PND has been considered and treated as a symptom of sinonasal pathology. It has also been shown, along with Gastroesophageal reflux disease (GERD) and asthma, to be a major contributor to the development of chronic cough. PND refractory to treatment aimed at sinonasal disease is sometimes treated with anti-GERD therapy. This treatment modality is based on clinical experience. To date, there are no studies in the literature to support a causal relationship between PND and extraesophageal reflux (EER). In a case control study of patients with and without esophagitis El-Serag et al reported a significant association (odds ratio 1.6, 95%CI 1.4-1.8) between sinusitis and GERD. A later study by Ulualp et al in 11 CT confirmed cases of chronic sinusitis resistant to therapy with conventional sinus therapies they found a significantly higher prevalence of hypopharyngeal acid exposure in the sinusitis group than controls. Recently, in an open label prospective pilot trial, DiBaise et al treated 11 patients with sinusitis and 19 GERD patients with omeprazole 20mg bid for 3-months. 9/11 sinusitis patients were found to have GERD by pH monitoring and there was moderate (25-89%) improvement in the sinus symptoms in the omeprazole treated group. However, there are currently no placebo-controlled trials assessing efficacy of PPI's in patients with PND.

Eligibility Criteria:
Inclusion Criteria:

* Negative RAST inhalant allergy panel OR negative skin testing (Group A)
* Positive RAST or Positive skin testing AND insufficient response to all of the following: (Group B)

  * Allergen avoidance
  * Topical nasal steroids
  * Allergy shots if indicated
  * Antihistamines
  * Negative CT sinuses (coronal)
  * \< 4mm of mucosal thickening and \< 3 sinus sites
  * Absence of air-fluid levels
  * Negative anterior rhinoscopy
  * Absence of pus, crusts on mucosal surfaces

Exclusion Criteria:

* Age \< 18
* Pregnancy, confirmed by urine pregnancy test at day of randomization
* Ciliary dyskinesia
* Immune deficiency
* Cystic fibrosis
* Diagnosis of acute sinusitis or chronic RS (AAO-HNS)
* Active use of topical decongestant
* Use of PPI within the last 30 days
* Previous fundoplication
* Uncontrolled thyroid disease
* Isolated chronic cough without the symptom of post nasal drip
Is Phonophoresis Treatment Effective?

The specimens from patients as knee osteoarthritis diagnosed who was applied ibuprofen phonophoresis will be analyzed.


Eligibility Criteria:
Inclusion Criteria:

* having diagnosed as osteoarthritis

Exclusion Criteria:

* surgery at knee
* trauma at knee
Neurally Adjusted Ventilatory Assist vs Proportional Assist Ventilation

This study aims to assess whether neurally adjusted ventilatory assist or proportional assist ventilation is more effective in infants born prematurely with evolving or established bronchopulmonary dysplasia

Despite improvements in survival rates of extremely preterm born infants, the incidence of bronchopulmonary dysplasia (BPD) remains unchanged over the last two decades. As invasive ventilation is frequently necessary and indeed life saving, numerous ventilator strategies have been developed to reduce damage to the developing lung. Synchronisation of mechanical breaths with the patient's respiratory effort offers the theoretical benefit of improving oxygenation and ventilation, requiring lower ventilator pressures, fewer air leaks and increased patient comfort.

Recently, novel modes of ventilation have been introduced that aim to improve upon conventional ventilation. During both proportional assist ventilation (PAV) and neurally-adjusted ventilatory assist (NAVA), respiratory support is servo-controlled based on continuous input from the baby's respiratory effort. Both aim to improve synchronization of the timing of the respiratory cycle and also to vary the level of support offered breath-to-breath in proportion to the respiratory effort of the patient.

During proportional assist ventilation (PAV), the ventilator can vary inflation pressure in phase with both volume change and flow change in order to offload both elastic and resistive components of the work of breathing. We have previously shown that PAV, compared to ACV, reduces the oxygenation index and improves respiratory muscle strength in infants born prematurely who remain ventilated at or beyond one week of life .

Neurally adjusted ventilatory assist (NAVA) utilises the electrical activity of the diaphragm to trigger the ventilator. A modified nasogastric feeding tube with a series of electrodes allows monitoring of the diaphragmatic electromyogram (Edi). The waveform of the Edi is used to trigger and control ventilator support. We have recently shown that NAVA compared to ACV results in a lower oxygenation index in infants born prematurely who remain ventilated at or beyond one week of life.

Both PAV and NAVA have been shown to have advantages above conventional triggered ventilation in neonates, but they have not been compared to each other. Our aim is to determine whether NAVA or PAV is more effective in prematurely born neonates with evolving or established BPD.

Eligibility Criteria:
Inclusion Criteria:

* Born at less than 32 weeks gestation
* ventilated at or beyond one week of life

Exclusion Criteria:

* major congenital abnormalities
Metabolic FingerPrinting

The MetaPrint study aims to characterize the metabolic fingerprint of genetic diseases in order to enhance knowledge on the physiological disease status and establish so new tools for diagnosing, monitoring and personalizing treatment of genetic diseases.


Eligibility Criteria:
Inclusion Criteria:

* Informed consent is obtained from the participant or from the parent/ legal guardian
* The participant is 2 months or older
* The participant is diagnosed with a genetic disease
* The participant is a first degree relative of a subject diagnosed with a genetic disease

Exclusion Criteria:

* Informed consent is not obtained from the participant or from the parent/ legal guardian
* The participant is younger than 2 months
* The participant is not diagnosed with a genetic disease
* The participant is not a first degree relative of a subject diagnosed with a genetic disease
Laparoscopic Sleeve Gastrectomy in Severely Obese Adolescents: Effects on Metabolism

Severe obesity (SO), defined as BMI≥95th percentile, has increased worldwide among adolescents. American studies estimated that 1.3-2.8% of 12-19-year-old individuals have a BMI \>40 kg/m2 or a BMI \>35 kg/m2 with at least one serious co-morbidity. The immediate and long-term risks associated with SO in adolescents include cardiovascular and metabolic diseases, obstructive sleep apnoea and nonalcoholic fatty liver disease. However, the results of sleeve gastrectomy in adolescents are still uncertain.

Objective and hypotheses: Investigators aimed to assess the long-term safety, efficacy, and cardiovascular risk changes of laparoscopic sleeve gastrectomy in adolescents with SO.

Method: Longitudinal retrospective study of 22 adolescents with SO who underwent laparoscopic sleeve gastrectomy. Clinical and metabolic variables immediately before surgery and after 6, 12, 18 and 24 months were assessed.


Eligibility Criteria:
Inclusion Criteria:

* ages of 14 and 19
* submitted to LSG between 2007 and 2014.
* attended the child obesity clinic of the pediatric endocrinology department of the Instituto da Criança da Universidade de São Paulo (Children's Institute of University of São Paulo).
* received clinical and pharmacological treatment for at least 6 months before surgery and were followed by a multidisciplinary team including a pediatric endocrinologist, a nutritionist, a psychologist and a physical educator.
* BMI \> 40 kg/m2 or BMI \> 35 kg/m2 with comorbidities and failed to achieve significant weight loss (10% of initial weight at 6 months) through clinical treatment.
* Both the patients and their guardians were informed about the risks and benefits of surgery and provided informed consent.

Exclusion Criteria:

* it was a retrospective study
Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis

The purpose of this study is to investigate the effect of vitamin D repletion on disease activity and disability in patients with rheumatoid arthritis.

The investigators hypothesize that rheumatoid arthritis (RA) patients with vitamin D deficiency have greater disease activity and disability, compared to RA patients with normal vitamin D levels. The investigators also hypothesize that vitamin D treatment in these deficient patients will result in a decrease in RA disease activity and disability.


Eligibility Criteria:
Inclusion Criteria:

* Rheumatoid Arthritis diagnosed according to American College of Rheumatology (ACR) criteria
* ages 18-75 years

Exclusion Criteria:

* Diagnosis of any other autoimmune disease:

such as Lupus, Scleroderma, Myositis, Sjogren's Syndrome, Vasculitis'

* Having any of the following conditions with in the last 6 months Hypercalcemia, Hyperparathyroidism, Active tuberculosis (TB), Lymphoma or any other type of cancer, Sarcoidosis, Seizure, Stroke
* Severe heart problems
* Kidney failure requiring dialysis treatment
* Liver failure or cirrhosis of the liver
* Poorly controlled hypertension
* current uncontrolled Depression, Bipolar Disorder, or other Psychiatric illness
* Pregnancy
Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test

This study is designed to test the hypothesis that the Synchronous Neural Interaction™ Test is useful for diagnosing Probable Alzheimer's Disease according to standard criteria. Subjects diagnosed with Alzheimer's Disease as well as age-matched normal control subjects will be evaluated for symptoms of Alzheimer's Disease and those meeting inclusion criteria will undergo a brief, non-invasive scan of brain function using a magnetoencephalography (MEG). The scan itself lasts 1 minute while the subject is asked to stare at a dot projected in front of them on a video screen. Orasi Medical believes that patterns of brain activity measured at rest are indicative of Alzheimer's Disease pathology.

The protocol is amended to add a follow-up assessment for previously enrolled and completed subjects who agree to participate in the follow-up assessment approximately 9 - 15 months after initial study enrollment. Subjects who agree to participate in the follow-up assessment will undergo the same standardized tests and MEG scan procedure as completed in the initial study.


Eligibility Criteria:
Inclusion Criteria:

1. Subject is between 18 and 90 years of age
2. i. Provide written informed consent for study participation, OR ii. Provide written assent to study participant accompanied by the provision of written informed by the subject's legally authorized representative (LAR); see Section 8. Informed Consent for details of the procedures use to meet these study inclusion criteria
3. Have one of the following clinical diagnoses or conditions:

   * Probable AD according to the NINCDS-ADRDA criteria
   * Possible AD according to the NINCDS-ADRDA criteria
   * Prodromal AD according to criteria described by Dubois \& Albert (2004)
   * Normal control subject

Exclusion Criteria:

1. Have a significant non-AD neurological condition including Parkinson's Disease, Vascular Dementia, Lewy Body Dementia or Frontal Temporal Dementia, human immunodeficiency virus, multiple sclerosis, epilepsy, or severe traumatic brain injury.
2. Have dementia due to multiple etiologies (e.g. mixed dementia)
3. Show the presence of prominent disturbances in gait thought to be associated with Parkinsonism.
4. Show prominent changes in personality or social conduct prior to the onset of prominent cognitive dysfunction
5. Have a Modified Hachinski Ischemia Scale score of greater than 4
6. Have a history of primary psychotic disorder (e.g schizophrenia, schizoaffective disorder, delusional disorder) or bipolar disorder
7. Have a lifetime or current history of alcohol or substance abuse/dependence
8. Have had an MRI two weeks prior to completing the MEG scan
9. Have metal braces or pacemaker that may interfere with the MEG scan
10. Are unable to complete the MEG scan procedure

Follow-up Assessment Inclusion Criteria:

Subjects who completed Protocol ADG 08-01 will be contacted and invited to participate in the follow-up assessment.
The Effect of IABP Early Insertion on Mortality in Post Cardiac Arrest Patients With Acute Coronary Syndrome

The prevalence of cardiac arrests is still high worldwide. Despite the return of spontaneous circulation (ROSC), mortality and morbidity in post cardiac arrest patients is reported high. Comprehensive management is essential in treating patients with post cardiac arrest syndrome. Adequate circulatory stability is achieved with fluid therapy, vasoactive drug therapy, and consideration of mechanical support. Intra-Aortic Ballon Pump (IABP) is one of the most feasible and available mechanical support in developing countries including Indonesia.

There are several benefits of IABP reported in acute myocardial infarction complicated with cardiogenic shock. Nevertheless, the IABP-SHOCK II study revealed contradictive result which is IABP support was not improving mortality in acute myocardial infarction complicated with cardiogenic shock after revascularization. Other study, Korean Acute Myocardial Infarction Registry (KAMIR), also reported no benefits of IABP support in cardiogenic shock patients. But, the study the investigators mentioned earlier is a registry study, attributed to selection bias and several confounding factors resulting mismatch in population. There are no consideration to IABP time of initiation and duration of use in both studies.

The Investigator is aiming to prove the early insertion of IABP to a better outcome compared with the absence of early IABP. The objective of the study is to assess mortality in post cardiac arrest syndrome patients with early insertion of IABP support. A total of 102 subjects will be enrolled in this study, divided into IABP and non-IABP group. The primary outcome is in-hopital-mortality, and various indicators in the pathomechanisme of post cardiac arrest syndrome will be measured in 30 minutes and 6 hours after ROSC. Effective lactate clearance, IL-6, Beclin-1, Caspase-3, a-vO2 diff, and ScvO2, cardiac output, VTI, TAPSE and ejection fraction will be measured and analized between the two groups.


Eligibility Criteria:
Inclusion Criteria:

1. Age greater than 18 and less than 75 years.
2. Post cardiac arrest syndrome patients with decreased level of consciousness (cerebral performance categories (CPC) more than 1) and hypotension (systolic blood pressure less than 100)
3. Experiencing successful cardiac rescucitation following cardiac arrest

Exclusion Criteria:

1. History of stroke (based on interview)
2. Unequal pupil
3. Previous use of IABP
4. Aorta regurgitation
5. Brugada syndrome and congenital long QT

Drop-out Criteria:

1. Participants who died before IABP insertion
2. The family requests for a termination of treatment.
3. Anemia caused by bleeding with hemoglobin decrement by \>3 gr/dL
4. Ankle brachial index(ABI) less than 0,8
Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation

The purpose of this study is to determinate if mediyoga has effects in quality of life, heart rate variability, blood pressure , heart rate in patients with paroxysmal atrial fibrillation (PAF).

This is randomized prospective pilot study. Eighty patients from Danderyd hospital, Stockholm, Sweden were randomized to either mediyoga group or control group. The mediyoga group were completing yoga for one hour, once a week for 12 weeks together with usual treatment. The controlgroup had only usual treatment.The usual treatment consists of pharmaceutical, cardio version and ablation. Quality of life ( SF-36, EQ-5d), blood pressure, heart rate and 24-hours ekokardiografi were measured at baseline and after twelve weeks.A follow up after six months was accomplished with SF-36 and EQ-5d, bloodpressure and heart rate.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of PAF

Exclusion Criteria:

* The exclusions criteria were multiple concurrent medical conditions and/or cognitive dysfunction (in the diagnosis of e.g. mental illness), considered not to be able to carry out yoga owing to ability to move and those who have difficulties to understand the Swedish language.
Stair Descending vs. Stair Ascending Exercise

The aim of the present project is to compare the acute and chronic effect of stair descending versus stair ascending exercise on muscle damage and performance in elderly males with chronic heart failure.

Study design:

Twelve elderly males with chronic heart failure, New York Heart Association class I-II, will participate in this study. Participants will be allocated into two equally-sized groups: a stair descending group (n = 6) and a stair ascending group (n = 6). At the beginning of the study, the volunteers will perform an acute bout of stair descending or stair ascending exercise on an automatic escalator (4 sets of 3 min each, speed will be set at 45 steps∙min-1). Step height will be 20.5 mm. Before and at day 2 post exercise, physiologic measurements will be performed and blood samples will be collected. Then, participants will carry out six weeks of stair descending or ascending training consisting of three exercise sessions per week (the first two weeks the speed will be set at 45 steps∙min-1, the next two weeks at 50 steps∙min-1 and the last two weeks at 55 steps∙min-1 for both groups). Afterward, they will repeat the acute stair descending or ascending protocol, as carried out at the beginning of the study, and the same physiologic measurements will be performed and blood samples will be collected.

Measurements:

Isometric (at 90 knee flexion), concentric and eccentric peak torque at 60o∙s-1of quadriceps femoris, pain-free range of motion, delayed onset muscle soreness and creatine kinase will be measured.

Eligibility Criteria:
Inclusion Criteria:

* chronic heart failure (New York Heart Association class I-II)
* subject provides written informed consent
* personal physician of the participants provides written informed consent

Exclusion Criteria:

* smoker
* consumed any nutritional supplement the last 3 months
* performed intense eccentric exercise the last 6 months
* non Caucasian
Low-Fat Vegan Diet Versus a Mediterranean Diet on Body Weight

This randomized, cross-over trial aims to assess changes in body weight, plasma lipids, insulin sensitivity, and postprandial metabolism with a low-fat, plant-based diet and a Mediterranean diet, both followed for 4 months.

In a 36-week cross-over trial, overweight adults will consume a low-fat vegan diet and a Mediterranean diet in two separate 16-week phases. Changes in body weight will be the primary dependent variable. In addition, plasma lipid concentrations, insulin sensitivity, and postprandial metabolism will also be assessed and changes over time will be compared between the two diets.

Participants will be randomly assigned to start either a low-fat vegan diet or a Mediterranean diet for 16 weeks. Both groups will receive weekly classes and support, and will be asked to make no changes to their exercise patterns for the study period. After a 4-week washout period, participants will cross over to the second dietary intervention for another 16 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Men and women age ≥18 years of age
* Body mass index 28-40 kg/m2

Exclusion Criteria:

* Diabetes mellitus type 1, history of any endocrine condition that would affect body weight, such as thyroid disease, pituitary abnormality, or Cushing's syndrome
* Smoking during the past six months
* Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use
* Use of recreational drugs in the past 6 months
* Use within the preceding six months of medications that affect appetite or body weight, such as estrogens or other hormones, thyroid medications (unstable dose within the preceding 6 months), systemic steroids, antidepressants (tricyclics, MAOIs, SSRIs), antipsychotics, lithium, anticonvulsants, appetite suppressants or other weight-loss drugs, herbs for weight loss or mood, St. John's wort, ephedra, beta blockers
* Pregnancy or intention to become pregnant during the study period, as verified by self--- - Unstable medical or psychiatric illness
* Evidence of an eating disorder
* Likely to be disruptive in group sessions
* Already following a low-fat vegan diet or Mediterranean diet
* Lack of English fluency
* Inability to maintain current medication regimen
* Inability or unwillingness to participate in all components of the study
* Intention to follow another weight-loss method during the trial
Lymphedema Treatment in Head and Neck Cancer Patients

The purpose of this research is to evaluate the result of treatment for neck lymphedema on throat pressure in patients who have received radiation therapy for head and neck cancer.

Lymphedema is a failure of lymphatic system to transfer fluid from the connective tissue to the circulatory system. The lymphedema seen in patients treated for head and neck cancer can be seen externally on the neck and face, as well as internally in the lining of the throat. In this study, the investigators plan to treat the external lymphedema with a device called the Flexitouch Plus, which is already approved by the Food and Drug Administration (FDA) for lymphedema treatment, and to measure the degree of internal lymphedema using a pressure sensor to detect throat muscle pressure before and after the treatment with the Flexitouch Plus device.

Eligibility Criteria:
Inclusion Criteria:

* Patients with tumors of the nasopharynx, oral cavity, oropharynx, hypopharynx, or larynx who will have radiation therapy as part of their treatment plan
* Both male and females
* 18 to 100 years of age

Exclusion Criteria:

* Significant surgical resection of pharyngeal constrictor muscles
* Patients with persistent or recurrent disease
* Patients who have contraindications to use Flexitouch Plus device